Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis

Shen, Xiawei; Zhu, Yali; Xiao, Zuixuan; Dai, Xuemei; Liú, Dan; Li, Lin; Xiao, Bao-Lai

doi:10.1016/j.amjms.2017.03.025

Cited by 14 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…182,183 In addition, the antiviral drug ribavirin catalyses ACHY conversion to adenosine and Hcy and then blocks the activity of ACHY. [141][142][143][144][145][146] 3′keto aristeromycin and 2-fluoroadenosine displayed the in vivo suppression activity of ACHY. 147 Hao et al screened thirteen compounds inhibiting ACHY by ChemMapper and SciFinder Scholar, which greatly increased the candidates for clinical research, and found that Compound 13 exerted considerable inhibitory effects on breast cancer and prostate cancer [152][153][154] (Figure 3 and Table 4).…”

Section: Achy Inhibitorsmentioning

confidence: 98%

“…Cu 2+ inhibited the enzymatic activity of ACHY by inducing the release of NAD + cofactors 182,183 . In addition, the antiviral drug ribavirin catalyses ACHY conversion to adenosine and Hcy and then blocks the activity of ACHY 141–146 . 3′‐keto aristeromycin and 2‐fluoroadenosine displayed the in vivo suppression activity of ACHY 147 .…”

Section: Target 1c Metabolism Enzymes For Cancer Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Targeting one‐carbon metabolism for cancer immunotherapy

Ren,

Wang,

Zheng

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundOne‐carbon (1C) metabolism is a metabolic network that plays essential roles in biological reactions. In 1C metabolism, a series of nutrients are used to fuel metabolic pathways, including nucleotide metabolism, amino acid metabolism, cellular redox defence and epigenetic maintenance. At present, 1C metabolism is considered the hallmark of cancer. The 1C units obtained from the metabolic pathways increase the proliferation rate of cancer cells. In addition, anticancer drugs, such as methotrexate, which target 1C metabolism, have long been used in the clinic. In terms of immunotherapy, 1C metabolism has been used to explore biomarkers connected with immunotherapy response and immune‐related adverse events in patients.MethodsWe collected numerous literatures to explain the roles of one‐carbon metabolism in cancer immunotherapy.ResultsIn this review, we focus on the important pathways in 1C metabolism and the function of 1C metabolism enzymes in cancer immunotherapy. Then, we summarise the inhibitors acting on 1C metabolism and their potential application on cancer immunotherapy. Finally, we provide a viewpoint and conclusion regarding the opportunities and challenges of targeting 1C metabolism for cancer immunotherapy in clinical practicability in the future.ConclusionTargeting one‐carbon metabolism is useful for cancer immunotherapy.

show abstract

Section: Achy Inhibitorsmentioning

confidence: 98%

Section: Target 1c Metabolism Enzymes For Cancer Immunotherapymentioning

confidence: 99%

Targeting one‐carbon metabolism for cancer immunotherapy

Ren,

Wang,

Zheng

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…Ribavirin, an antiviral medication, has been identified as an inhibitor of eukaryotic initiation factor 4E (eIF4E) [ 91 ]. Shen et al demonstrates that ribavirin acts on TC cells by inhibiting eIF4E/β-catenin signaling, suggesting that ribavirin has the potential to be repurposed for TC treatment and highlighting the therapeutic value of inhibiting eIF4E-β-catenin in TC [ 92 ]. Other research showed that cidofovir (CDV) can reduce follicular thyroid carcinoma cell viability and apoptosis induction in a virus-independent manner.…”

Section: Advanced Therapymentioning

confidence: 99%

The Potential Role of Virus Infection in the Progression of Thyroid Cancer

Wu,

Jiang,

et al. 2024

World J Oncol

View full text Add to dashboard Cite

Multiple factors have engaged in the progression of thyroid cancer (TC). Recent studies have shown that viral infection can be a critical factor in the pathogenesis of TC. Viruses, such as Epstein-Barr virus (EBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may play an essential role in the occurrence, development, and even prognosis in TC. This review mainly explored the potential role of viral infection in the progress of TC. The possible mechanisms could be recognizing the host cell, binding to the receptors, affecting oncogenes levels, releasing viral products to shape a beneficial environment, interacting with immune cells to induce immune evasion, and altering the pituitary-thyroid axis. Thus, comprehensive knowledge may provide insights into finding molecular targets for diagnosing and treating virus-related TC.

show abstract

“…Combination therapies with ribavirin have been studied in several head and neck cancers, including human papillomavirus (HPV)-associated head and neck squamous cell carcinomas (HNSCC), and thyroid cancers. Preclinical xenograft experiments involving eIF4E-dependent HNSCC cell lines have provided proof-of-principle of anticancer effects of ribavirin on these tumors (13,14). In 2017, a phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB HPV-associated HNSCC was reported (15).…”

Section: Head and Neck: Squamous Cell Carcinoma And Thyroid Cancermentioning

confidence: 99%

The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?

Casaos

Gorelick

Huq

et al. 2019

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The growing cost of medical care worldwide, particularly in oncology, has incentivized researchers and physicians to repurpose clinically used drugs to alleviate the financial burden of drug development and offer potential new therapeutics. Recent works have demonstrated anticancer properties of the FDA-approved drug ribavirin, a synthetic guanosine analogue and antiviral molecule used over the past four decades for the treatment of hepatitis C. The efficacy of ribavirin in cancer has been explored through several preclinical models and ongoing clinical trials in multiple cancers, including acute myeloid leukemia, oropharyngeal squamous cell carcinoma, and metastatic breast cancer. In this review, we summarize the role of ribavirin as an antiviral medication and focus our attention on its recent use as an antitumoral agent. We highlight current knowledge of the potential use and mechanisms of action of ribavirin in cancer. Because current therapeutics for patients with cancer still fail to cure, introducing new forms of treatment is essential. Converging evidence suggests that ribavirin represents a promising addition to a generation of newly repurposed safe and effective anticancer agents.

show abstract

Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis

Cited by 14 publications

References 31 publications

Targeting one‐carbon metabolism for cancer immunotherapy

Targeting one‐carbon metabolism for cancer immunotherapy

The Potential Role of Virus Infection in the Progression of Thyroid Cancer

The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?

Contact Info

Product

Resources

About